Detalles de la búsqueda
1.
The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis.
Drugs R D
; 13(4): 243-52, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24142473
2.
Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin.
Adv Ther
; 29(5): 442-55, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22644963
3.
Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.
Clin Drug Investig
; 32(5): 303-17, 2012 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22420526
4.
Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections.
Clin Ophthalmol
; 6: 1987-96, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-23233796
5.
Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
Clin Ther
; 33(1): 13-26, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21397770
6.
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes.
Clin Ophthalmol
; 5: 1359-67, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-22034555
7.
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile.
Clin Ophthalmol
; 5: 1369-79, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-22034556
Resultados
1 -
7
de 7
1
Próxima >
>>